Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 102 results for "lacosamide"

Opinion/decision on a Paediatric Investigation Plan (PIP): ...

European Medicines Agency - Science, medicines, health An agency of the European Union Search for medicines Search European Medicines Agency, 2 weeks ago

10 images for lacosamide

MDLinx, 5 days ago
MDLinx, 5 days ago
MDLinx, 5 days ago
MDLinx, 5 days ago
MDLinx, 5 days ago
Pharmaceutical Technology, 2 weeks ago
MDLinx, 2 weeks ago
MDLinx, 2 weeks ago
MDLinx, 2 weeks ago
MDLinx, 2 weeks ago
Pharmaceutical Technology

Daiichi and UCB Biopharma partner to introduce epilepsy treatment Lacosamide in Japan

Japan-based Daiichi Sankyo has signed an agreement with UCB Biopharma to jointly commercialise Lacosamide for the treatment of patients with epilepsy in Japan. As part of the deal, UCB will manufacture and supply the product for commercialisation ...
 Pharmaceutical Technology2 weeks ago Daiichi Sankyo and UCB partner to commercialize epilepsy drug in Japan  Individual.com2 weeks ago Daiichi Sankyo, UCB to jointly commercialise lacosamide for epilepsy patients in Japan  PharmaBiz3 weeks ago Daiichi Sankyo : UCB to jointly commercialize epilepsy drug Lacosamide in Japan  4 Traders2 weeks ago

BRIEF-UCB announces partnership with Daiichi Sankyo in Japan

Nov 28 (Reuters) - UCB SA : * Announces partnership with Daiichi Sankyo for co-commercialization of Lacosamide in Japan * Says it will manufacture and supply product for commercialization, Daiichi Sankyo will manage distribution and book sales ...
 Reuters UK3 weeks ago

UCB's Phase III partial-onset seizures study meets primary endpoint

UCB SA, a biopharmaceutical company, has announced that the Phase III clinical study evaluating VIMPAT, or lacosamide, as adjunctive therapy in the treatment of Japanese and Chinese adult patients with partial-onset seizures has met its primary ...
 Individual.com1 month ago BRIEF-UCB Phase 3 clinical study on VIMPAT meets primary efficacy endpoint  Reuters UK1 month ago UCB enhances epilepsy presence in Japan and China: positive Phase 3 study for VIMPATĀ®  Noodls1 month ago

UCB reinforces its leadership in epilepsy at the 2014 Annual Meeting of the American Epilepsy Society (AES)

From the Wires - 24 UCB-sponsored presentations including new data on VIMPATĀ® (lacosamide) Dec. 3, 2014 01:00 AM BRUSSELS , Dec. 3,2014 /PRNewswire/ -- UCB, a global biopharmaceutical company with a focus on epilepsy treatment and ...
 Sys-Con India2 weeks ago

UCB and Daiichi Sankyo partner to bring Lacosamide to people living with epilepsy in Japan

 Noodls1 week ago DAIICHI SANKYO : UCB and Daiichi Sankyo partner to bring Lacosamide to people living with epilepsy in Japan  4 Traders2 weeks ago

Ranbaxy Laboratories : Patent Issued for Processes for Reducing Impurities in Lacosamide

By a News Reporter-Staff News Editor at Biotech Week -- Ranbaxy Laboratories Limited ( New Delhi , IN) has been issued patent number 8853453, according to news reporting originating out of Alexandria, Virginia , by NewsRx editors (see also ...
 4 Traders2 months ago

Abbott India, Sun Pharma, Lupin, GlaxoSmithKline & Cipla in tight contest at Pharmaleaders 2014 Awards in top categories

The race to the coveted & credible award for India's Most Admired & Powerful Brand, Corporate Practice, Investor Relations intensifies at 7th Annual Pharmaceutical Leadership Summit & Awards 2014 with a big voting in top four categories to select ...
 PharmiWeb2 weeks ago

Epilepsy Dominant at Lebanese Society of Neurology's 6th International Congress as Novel Treatment Option Unveiled

: Epilepsy featured prominently at the just-concluded 6 th Lebanese Society of Neurology International Congress, with the introduction of lacosamide a drug commercialized as VIMPAT that is available in tablets, oral solution or injections as an ...
 Executive Business Magazine3 weeks ago

Partial Seizure - Pipeline Review, H2 2014 - New Report Available

Global Markets Direct's, 'Partial Seizure - Pipeline Review, H2 2014', provides an overview of the Partial Seizure's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Partial Seizure, complete ...
 MoneyShow.com1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less